These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17564579)

  • 1. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?
    Faunce TA
    Med J Aust; 2007 Aug; 187(4):240-2. PubMed ID: 17564579
    [No Abstract]   [Full Text] [Related]  

  • 2. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
    Hamilton C; Lokuge B; Denniss R
    Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
    [No Abstract]   [Full Text] [Related]  

  • 3. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme.
    Sainsbury P
    Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920
    [No Abstract]   [Full Text] [Related]  

  • 4. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
    Harvey K
    Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PBS in a globalised world: free trade and reference pricing.
    Searles A
    Aust Health Rev; 2009 May; 33(2):186-91. PubMed ID: 19563307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme.
    Searles A; Jefferys S; Doran E; Henry DA
    Med J Aust; 2007 Aug; 187(4):236-9. PubMed ID: 17564580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free trade in pharmaceuticals.
    Outterson MK
    Med J Aust; 2004 Sep; 181(5):260-1. PubMed ID: 15347274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
    Harvey KJ; Faunce TA; Lokuge B; Drahos P
    Med J Aust; 2004 Sep; 181(5):256-9. PubMed ID: 15347273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
    Faunce TS; Tomossy GF
    Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic drugs: international trends and policy developments in Australia.
    Lofgren H
    Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Democratic discussion in newspaper reporting of the Australia-United States Free Trade Agreement.
    Sykes R
    J Law Med; 2008 Oct; 16(2):356-70. PubMed ID: 19010009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug policy down under: Australia's pharmaceutical benefits scheme.
    Duckett SJ
    Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
    Faunce TA
    Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    Freemantle N
    Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.
    Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR
    Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australia's pharmaceutical cost sharing policy: reducing waste or affordability?
    Doran E; Robertson J
    Aust Health Rev; 2009 May; 33(2):231-40. PubMed ID: 19563311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inequality in health insurance reform: are the elderly more at risk?
    Phillips CR; Schuler DK; Jacobs EW
    J Health Care Mark; 1994; 14(4):14-9. PubMed ID: 10154632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.